洞察市场格局
解锁药品研发情报

客服电话

400-9696-311
医药数据查询

首页 临床进展

【ChiCTR2600119910】

查看原文
立即下载
基本信息
登记号

ChiCTR2600119910

试验状态

结束

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2026-03-05

临床申请受理号

/

靶点

/

适应症

Thyroid Cancer

试验通俗题目

/

试验专业题目

/

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

联系人通讯地址
请登录查看
临床试验信息
试验目的

1.Discover new genetic mutations or variants associated with thyroid cancer that have not been previously documented 2.Analyze Common Mutations in Thyroid Cancer-Related Genes 3.Assess the Clinical Utility of NGS in Patient Management 4.Compare Genetic Variants Across Different Populations

试验分类
请登录查看
试验类型

连续入组

试验分期

其它

随机化

None

盲法

/

试验项目经费来源

None

试验范围

/

目标入组人数

45

实际入组人数

/

第一例入组时间

2024-10-01

试验终止时间

2025-09-30

是否属于一致性

/

入选标准

Patients were eligible for inclusion if they had a histopathologically confirmed diagnosis of PTC, underwent total thyroidectomy during the study period, and had available formalin-fixed, paraffin-embedded (FFPE) tumor tissue suitable for molecular analysis. Only cases with complete clinicopathological data, including demographic, biochemical, and tumor-related parameters, were enrolled.；

排除标准

Patients were excluded if they had any other histological type of thyroid cancer, presented with distant metastasis at the time of diagnosis, or had insufficient or poor-quality FFPE samples that failed DNA extraction or sequencing quality control. Individuals with recurrent thyroid cancer, previous thyroid surgery, radiotherapy, or systemic therapy were also excluded, as well as cases with incomplete medical records that could not be used for statistical evaluation.；

研究者信息
研究负责人姓名
请登录查看
试验机构

Sulaimani university

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

/

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

Sulaimani university的其他临床试验

更多

Sulaimani university的其他临床试验

更多

最新临床资讯

更多
摩熵医药企业版
50亿+条医药数据随时查
7天免费试用
体验产品